Cubist Pharmaceuticals announced that the FDA has approved a new administration method for Cubicin (daptomycin for injection) to include a once-a-day 2-minute intravenous (IV) injection.  Cubicin is already approved to be administered as a once-a-day 30-minute infusion in the treatment of methicillin-resistant Staphylococcus aureus (MRSA) complicated skin infections and bacteremia.

For more information call (866) 793-2786 or visit www.cubicin.com.